Galapagos NV GXE.DE · Stock Open Galapagos NV in new tab
Galapagos NV Analysis (GXE.DE)
Is Galapagos NV a good investment? Galapagos NV (GXE.DE) is currently trading at 24.46 EUR.
In terms of valuation, the stock trades at a P/E ratio of 3.31. This relatively low multiple may signal that Galapagos NV is undervalued compared to historical market norms.
Investor FAQ
Does Galapagos NV pay a dividend?
No, it does not currently pay a dividend.
What asset class is Galapagos NV?
Galapagos NV is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
Company Profile
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Community Discussion